Cellectis SA (FR:ALCLS)
:ALCLS
Want to see FR:ALCLS full AI Analyst Report?
ALCLS Stock Chart & Stats
€3.86
-€0.02(-1.32%)
At close: 4:00 PM EST
€3.86
-€0.02(-1.32%)
Day’s Range― - ―
52-Week Range€1.23 - €4.84
Previous CloseN/A
Volume10.86K
Average Volume (3M)852.48K
Market Cap
€190.94M
Enterprise Value€332.96M
Total Cash (Recent Filing)€185.47M
Total Debt (Recent Filing)€108.49M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Jul 30, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume1,338,181
30 Day Avg. Volume852,477
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)€51.93M
Bulls Say, Bears Say
Bulls Say
Proprietary Gene‑editing PlatformCellectis' allogeneic gene‑editing platform is a durable competitive asset: off‑the‑shelf CAR‑T programs can scale manufacturing, lower per‑patient costs versus autologous approaches and enable multiple pipeline candidates, supporting repeatable long‑term commercial opportunities and partner interest.
Partnership/licensing Revenue ModelA partnership and licensing model provides recurring non‑product cash inflows and milestone potential that de‑risks development spending. Durable partner funding and service revenues can extend runway, share commercialization risk and help sustain R&D investment without sole reliance on product sales.
High Gross Margins And Sizable Asset BaseStrong historical gross margins and a sizable asset base indicate attractive unit economics once products scale and meaningful tangible resources to support R&D or collateralize financing. These structural strengths improve the odds of converting clinical success into commercially viable returns.
Bears Say
Deep And Persistent LossesSustained, large net losses erode shareholder equity and limit the company's ability to self‑fund trials or commercial launches. Persistent unprofitability increases dependency on external capital, raising dilution risk and constraining long‑term strategic flexibility until operating leverage improves.
Consistent Cash BurnMulti‑period negative operating and free cash flows demonstrate unreliable internal funding for development. Ongoing cash burn forces recurring fundraising or debt, which can dilute existing shareholders, increase financing costs, and limit the company's ability to pace trials or expand programs sustainably.
Rising Leverage And Shrinking EquityIncreasing leverage alongside declining equity reduces financial flexibility and raises solvency risk if cash flows do not improve. Higher debt burdens increase fixed obligations and cost of capital, limiting the firm's ability to pursue opportunistic licensing, partnerships or late‑stage development without unfavorable financing terms.
Cellectis SA News
ALCLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €1.23 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €190.94M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Jul 30, 2026 which is in 52 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -€0.153 earnings per share for the quarter, beating the consensus estimate of -€0.221 by €0.068.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.23.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.153 in its last earnings report, beating expectations of -€0.221. Following the earnings report the stock price went up 1.658%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in FR:ALCLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
ALCLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all FR:ALCLS earnings summariesTechnical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---